Jean-Yves Fagon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Yves Fagon has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Guerot
Hôpital Européen Georges Pompidou, Réanimation Médicale, Paris, France
2 shared publications Jean Chastre
Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie of Paris-6, France
2 shared publications- Jean-Luc Diehl
Paris Research Cardiovascular Center, INSERM UMR-S 970, Paris Cité Université , Paris
2 shared publications A Hance
1 shared publication- Christophe Faisy
Medical Intensive Care Unit, European Georges Pompidou Hospital (AP-HP), Université Paris Descartes, Sorbonne Paris Cité, 20 rue Leblanc, 75908 Paris, France
1 shared publication Claude Gibert
1 shared publication
Latest Publications
- Open Access
- 19 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 1-6
Ilio-psoas hematoma in the intensive care unit: a multicentric study
- 19 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 1-6
Open AccessIlio-psoas hematoma in the intensive care unit: a multicentric study
- 14 May 2015
- Published by JLE in Douleur et Analgésie
- Vol. 28 (2) , 91-92
Médecine chinoise et douleur, un exemple pour favoriser la complémentarité
- 14 May 2015
- Published by JLE in Douleur et Analgésie
- Vol. 28 (2) , 91-92
Médecine chinoise et douleur, un exemple pour favoriser la complémentarité
- 31 January 2011
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 3 (1) , 113-114
336 Gram-negative bacilli: a new independent risk factor of mortality after mediastinitis
- 31 January 2011
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 3 (1) , 113-114
336 Gram-negative bacilli: a new independent risk factor of mortality after mediastinitis
- Open Access
- 1 January 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 130
Biological markers and diagnosis of ventilator-associated pneumonia
- 1 January 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 130
Open AccessBiological markers and diagnosis of ventilator-associated pneumonia
- Open Access
- 21 July 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (4) , R120
Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status
Introduction: In septic patients, an unpredictable response to epinephrine may be due to pharmacodynamic factors or to non-linear pharmacokinetics. The purpose of this study was to investigate the pharmacokinetics of epinephrine and its determinants in patients with septic shock.Methods: Thirty-eight consecutive adult patients with septic shock were prospectively recruited immediately before epinephrine infusion. A baseline blood sample (C0) was taken to assess endogenous epinephrine, norepinephrine, renin, aldosterone, and plasma cortisol levels before epinephrine infusion. At a fixed cumulative epinephrine dose adjusted to body weight and under steady-state infusion, a second blood sample (C1) was taken to assess epinephrine and norepinephrine concentrations. Data were analyzed using the nonlinear mixed effect modeling software program NONMEM.Results: Plasma epinephrine concentrations ranged from 4.4 to 540 nmol/L at steady-state infusion (range 0.1 to 7 mg/hr; 0.026 to 1.67 μg/kg/min). A one-compartment model adequately described the data. Only body weight (BW) and New Simplified Acute Physiologic Score (SAPSII) at intensive care unit admission significantly influenced epinephrine clearance: CL (L/hr) = 127 × (BW/70)0.60× (SAPS II/50)-0.67. The corresponding half-life was 3.5 minutes. Endogenous norepinephrine plasma concentration significantly decreased during epinephrine infusion (median (range) 8.8 (1 – 56.7) at C0vs. 4.5 (0.3 – 38.9) nmol/L at C1,P< 0.001).Conclusions: Epinephrine pharmacokinetics is linear in septic shock patients, without any saturation at high doses. Basal neurohormonal status does not influence epinephrine pharmacokinetics. Exogenous epinephrine may alter the endogenous norepinephrine metabolism in septic patients.
- 21 July 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (4) , R120
Open AccessPharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status
Introduction: In septic patients, an unpredictable response to epinephrine may be due to pharmacodynamic factors or to non-linear pharmacokinetics. The purpose of this study was to investigate the pharmacokinetics of epinephrine and its determinants in patients with septic shock.Methods: Thirty-eight consecutive adult patients with septic shock were prospectively recruited immediately before epinephrine infusion. A baseline blood sample (C0) was taken to assess endogenous epinephrine, norepinephrine, renin, aldosterone, and plasma cortisol levels before epinephrine infusion. At a fixed cumulative epinephrine dose adjusted to body weight and under steady-state infusion, a second blood sample (C1) was taken to assess epinephrine and norepinephrine concentrations. Data were analyzed using the nonlinear mixed effect modeling software program NONMEM.Results: Plasma epinephrine concentrations ranged from 4.4 to 540 nmol/L at steady-state infusion (range 0.1 to 7 mg/hr; 0.026 to 1.67 μg/kg/min). A one-compartment model adequately described the data. Only body weight (BW) and New Simplified Acute Physiologic Score (SAPSII) at intensive care unit admission significantly influenced epinephrine clearance: CL (L/hr) = 127 × (BW/70)0.60× (SAPS II/50)-0.67. The corresponding half-life was 3.5 minutes. Endogenous norepinephrine plasma concentration significantly decreased during epinephrine infusion (median (range) 8.8 (1 – 56.7) at C0vs. 4.5 (0.3 – 38.9) nmol/L at C1,P< 0.001).Conclusions: Epinephrine pharmacokinetics is linear in septic shock patients, without any saturation at high doses. Basal neurohormonal status does not influence epinephrine pharmacokinetics. Exogenous epinephrine may alter the endogenous norepinephrine metabolism in septic patients.
- Open Access
- 1 January 2007
- Published by Springer Nature in Critical Care
- Vol. 11 (2) , 123
Is bronchoalveolar lavage with quantitative cultures a useful tool for diagnosing ventilator-associated pneumonia?
The results of a recently published Canadian study suggest that bronchoalveolar lavage and endotracheal aspiration are associated with similar clinical outcomes and similar overall use of antibiotics in critically ill patients with suspected ventilator-associated pneumonia (VAP). The study, however, does not provide convincing information on the best strategy to diagnose VAP, to accurately choose initial treatment and to exclude VAP in order to avoid administering antibiotics to patients without bacterial infection. In fact, this trial has several limitations or drawbacks: patients at risk for developing VAP due to Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus were excluded, far from the real-life scenario; a significant number of patients were receiving recent antimicrobial therapy at the time of sampling, with, consequently, difficult-to-interpret culture results; randomization of included patients for initial treatment – meropenem plus ciprofloxacin or meropenem alone – resulted in a high rate of inappropriate initial empirical therapy due to the absence of customization to local epidemiology; and the initial decision to treat and the re-evaluation at day 3 were, in fact, based on clinical judgment and not on direct examination and quantitative culture results. In summary, because antimicrobial treatment was initiated in all suspected patients and was rarely withheld in patients with negative cultures, the study does not suggest an appropriate strategy for improving the use of antibiotics in intensive care unit patients. Such a strategy has two requirements: immediate administration of adequate therapy in patients with true VAP, and avoidance of administering antibiotics in patients without bacterial infection.
- 1 January 2007
- Published by Springer Nature in Critical Care
- Vol. 11 (2) , 123
Open AccessIs bronchoalveolar lavage with quantitative cultures a useful tool for diagnosing ventilator-associated pneumonia?
The results of a recently published Canadian study suggest that bronchoalveolar lavage and endotracheal aspiration are associated with similar clinical outcomes and similar overall use of antibiotics in critically ill patients with suspected ventilator-associated pneumonia (VAP). The study, however, does not provide convincing information on the best strategy to diagnose VAP, to accurately choose initial treatment and to exclude VAP in order to avoid administering antibiotics to patients without bacterial infection. In fact, this trial has several limitations or drawbacks: patients at risk for developing VAP due to Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus were excluded, far from the real-life scenario; a significant number of patients were receiving recent antimicrobial therapy at the time of sampling, with, consequently, difficult-to-interpret culture results; randomization of included patients for initial treatment – meropenem plus ciprofloxacin or meropenem alone – resulted in a high rate of inappropriate initial empirical therapy due to the absence of customization to local epidemiology; and the initial decision to treat and the re-evaluation at day 3 were, in fact, based on clinical judgment and not on direct examination and quantitative culture results. In summary, because antimicrobial treatment was initiated in all suspected patients and was rarely withheld in patients with negative cultures, the study does not suggest an appropriate strategy for improving the use of antibiotics in intensive care unit patients. Such a strategy has two requirements: immediate administration of adequate therapy in patients with true VAP, and avoidance of administering antibiotics in patients without bacterial infection.
- 1 March 2006
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 27 (01) , 034-044
Diagnosis and Treatment of Ventilator-Associated Pneumonia: Fiberoptic Bronchoscopy with Bronchoalveolar Lavage Is Essential
The management of patients suspected of having ventilator-associated pneumonia (VAP) requires a strategy for diagnosis and treatment that is designated to: (1) identify patients with true lung bacterial infection; (2) determine the pathogen(s) responsible for pneumonia; (3) permit early selection of appropriate antimicrobial therapy; and (4) avoid indiscriminate administration of antibiotics. The use of bronchoscopic techniques to obtain bronchoalveolar lavage (BAL) specimens from the affected area in the lung allows definition of a strategy superior to that based exclusively on clinical evaluation. When BAL is performed before introduction of new antibiotics, it enables physicians to identify patients who need immediate treatment and help to select initial antibiotic therapy (with the results of direct examination of BAL liquid) and to withhold, deescalate, and/or optimize treatment (when the results of quantitative cultures are available), in a manner that is safe and well tolerated by patients. This strategy, based on clinical and bacteriological evaluation, prevents resorting to broad-spectrum drug coverage in all patients who develop signs and symptoms suggestive of pneumonia, thus minimizing the emergence of resistant flora, and redirects the search for another infection site.
- 1 March 2006
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 27 (01) , 034-044
Diagnosis and Treatment of Ventilator-Associated Pneumonia: Fiberoptic Bronchoscopy with Bronchoalveolar Lavage Is Essential
The management of patients suspected of having ventilator-associated pneumonia (VAP) requires a strategy for diagnosis and treatment that is designated to: (1) identify patients with true lung bacterial infection; (2) determine the pathogen(s) responsible for pneumonia; (3) permit early selection of appropriate antimicrobial therapy; and (4) avoid indiscriminate administration of antibiotics. The use of bronchoscopic techniques to obtain bronchoalveolar lavage (BAL) specimens from the affected area in the lung allows definition of a strategy superior to that based exclusively on clinical evaluation. When BAL is performed before introduction of new antibiotics, it enables physicians to identify patients who need immediate treatment and help to select initial antibiotic therapy (with the results of direct examination of BAL liquid) and to withhold, deescalate, and/or optimize treatment (when the results of quantitative cultures are available), in a manner that is safe and well tolerated by patients. This strategy, based on clinical and bacteriological evaluation, prevents resorting to broad-spectrum drug coverage in all patients who develop signs and symptoms suggestive of pneumonia, thus minimizing the emergence of resistant flora, and redirects the search for another infection site.
- Open Access
- 1 January 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (4) , 151
Acute respiratory failure in the elderly
With the current epidemiology of a growing advanced-age population and the specificities of critical illness in elderly patients, studies on this topic are appropriate. We need more clinical trials and evaluations of diagnostic and management procedures applied in the elderly, as well as studies designed to identify prognostic factors for inhospital mortality or mortality in the intensive care unit in the elderly. Studies evaluating long-term outcomes, including quality of life and costs, are also needed to try to define realistic goals for patients, families and physicians.
- 1 January 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (4) , 151
Open AccessAcute respiratory failure in the elderly
With the current epidemiology of a growing advanced-age population and the specificities of critical illness in elderly patients, studies on this topic are appropriate. We need more clinical trials and evaluations of diagnostic and management procedures applied in the elderly, as well as studies designed to identify prognostic factors for inhospital mortality or mortality in the intensive care unit in the elderly. Studies evaluating long-term outcomes, including quality of life and costs, are also needed to try to define realistic goals for patients, families and physicians.
- 1 January 2006
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 12 (s9) , 17-22
Targeted antibiotic management of ventilator-associated pneumonia
- 1 January 2006
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 12 (s9) , 17-22
Targeted antibiotic management of ventilator-associated pneumonia
- 1 March 2005
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 26 (1) , 97-104
Antimicrobial Treatment of Hospital-Acquired Pneumonia
- 1 March 2005
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 26 (1) , 97-104
Antimicrobial Treatment of Hospital-Acquired Pneumonia